News | July 21, 2022
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated ExtensiveStage Small Cell Lung Cancer
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
The research was supported by the BGU Coronavirus Challenge and the Israeli Ministry of Health.
The team built a multiple ionic device system, each of which had a lithium cobalt oxide channel arranged on a common lithium phosphorus oxynitride electrolyte
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
Collaboration in the industry needs to be institutionalised to drive the growth.
Gupta to retire at the end of his current term on May 12, 2022, after more than a decade of service, during which time Avantor has transformed into a global life sciences leader
Resolv ER may remedy leading causes of blindness in adults
He has more than 285 publications with 7,600 citations, 80 students have already been awarded Ph. D. degree under his able guidance and 20 postdoctoral associates have worked in his group
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Subscribe To Our Newsletter & Stay Updated
